The European Commission has approved the first biosimilar version of Actemra/RoActemra, Roche’s $3 billion blockbuster, from German drugmaker Fresenius Kabi. The biosimilar of IL-6 inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback